ProfileGDS5678 / 1445862_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 75% 76% 75% 72% 78% 76% 77% 74% 76% 77% 76% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0740476
GSM967853U87-EV human glioblastoma xenograft - Control 25.2401977
GSM967854U87-EV human glioblastoma xenograft - Control 34.9347475
GSM967855U87-EV human glioblastoma xenograft - Control 45.2283276
GSM967856U87-EV human glioblastoma xenograft - Control 55.007775
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5711472
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2207178
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0705576
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1923677
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8660874
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0675276
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2513277
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0443476
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0720576